- recruitingPhase II and Phase III (Integrated)
ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B
The ATLAS-PEDS study is testing a preventative medicine called fitusiran in young boys aged 1 to 11 with haemophilia A or B. Researchers want to see how safely and effectively it lowers a blood protein called antithrombin to help the blood clot more easily and prevent bleeds.
Italy · Spain - active not recruitingPHASE3
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
This study looks closely at a new medicine called fitusiran for men with haemophilia A or B. It aims to see how safe the medicine is over a long time and how well it prevents bleeding, as well as if it improves quality of life.
United States · Australia · Canada - recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
This study is testing a new medicine, Fitusiran, for boys aged 1 to 11 with severe haemophilia A or B. It aims to see how well it prevents bleeding and if it's safe. Some boys will receive Fitusiran for the first time, while others have already been taking it.
United States · Belgium · Brazil - recruitingNA
Trial of an Exercise Intervention for Children With Haemophilia
This study looks at whether a special exercise programme can help boys aged 6-12 with haemophilia. The aim is to see if strengthening muscles can improve their joint health, reduce pain, and help them join in more activities with friends, compared to their usual care.
United Kingdom